Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Continuous, nonconventional sunitinib dosing viable in metastatic renal cell carcinoma

20 Dec 2019

Alternative dosing regimens of sunitinib are feasible and appear to be more effective than standard dosing for the treatment of patients with metastatic renal cell carcinoma, reports a new study.

The investigators enrolled metastatic renal cell carcinoma patients treated with sunitinib between 1 July 2007 and 1 July 2011. They performed a retrospective review of medical records and dispensing data to categorize sunitinib dosing as intermittent (4 weeks treatment followed by 2 weeks rest), continuous (continuous daily dosing) or nonconventional (2 weeks on/1 week off).

Overall survival associated with the different dosing regimens was the primary outcome. Secondary outcomes were progression-free survival and incidence of treatment cessation due to adverse effects.

Of the 180 patients included, 120 (67 percent) received intermittent dosing, 32 (18 percent) continuous dosing and 28 (16 percent) nonconventional dosing.

Overall survival was comparable between continuous and intermittent dosing regimens (median, 13 vs 9 months; hazard ratio [HR], 0.67, 95 percent confidence interval, 0.43–1.06; p=0.088) and significantly better with nonconventional vs intermittent dosing (median, 23 vs 9 months; HR, 0.55, 95 percent CI, 0.34–0.90; p=0.016).

Compared with intermittent dosing, both continuous (median, 9 vs 4 months; HR, 0.61, 95 percent CI, 0.40–0.94; p=0.025) and nonconventional dosing (median, 10 vs 4 months; HR, 0.61, 95 percent CI, 0.39–0.95; p=0.03) were associated with longer progression-free survival.

One in five patients (20 percent) stopped treatment with sunitinib due to adverse effects. This finding was similar to that of previous sunitinib trials.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.